CC Chemokine Receptor Type 5 Market Report 2024

The CC chemokine receptor type 5 market size has grown rapidly in recent years. It will grow from $1.27 billion in 2023 to $1.4 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth during the historic period can be attributed to several factors such as increased government funding, collaborations in research and development (R&D), public health campaigns, public-private partnerships, and the discovery of CCR5.

The CC chemokine receptor type 5 market size is expected to see rapid growth in the next few years. It will grow to $2.07 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The anticipated growth during the forecast period can be attributed to several factors, the ongoing prevalence of HIV/AIDS, advancements in healthcare infrastructure, economic incentives, rising demand for healthcare services, and overall economic growth. Major trends expected during this period include expanded research on cancer treatments, development of combination therapies, advancements in pharmaceutical manufacturing, strategic collaborations and partnerships, and an increase in clinical trials.

The growing prevalence of chronic diseases is anticipated to drive the expansion of the CC chemokine receptor type 5 (CCR5) market. Chronic diseases are becoming more common due to factors such as an aging population and increasing rates of lifestyle-related issues such as poor diet, lack of physical activity, and obesity. CCR5 plays a crucial role in chronic diseases such as HIV, where it acts as a coreceptor, allowing the virus to enter and infect immune cells, thus contributing to disease progression. For example, in October 2023, the Joint United Nations Programme on HIV/AIDS, a global initiative based in Switzerland, reported that in 2021, approximately 38.7 million people were living with HIV, which increased to 39 million in 2022. During 2022, there were 1.3 million new HIV infections. Consequently, the rising prevalence of chronic diseases is fueling growth in the CCR5 market.

Companies in the CCR5 market are focusing on developing new drugs, such as CCR5 antagonists, to maintain a competitive edge. CCR5 antagonists are medications that block the CCR5 receptor on immune cells, preventing certain pathogens such as HIV from binding and entering these cells, thereby inhibiting infection and influencing immune responses. For instance, in February 2024, CytoDyn Inc., a US-based biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on leronlimab, a CCR5 antagonist also known as PRO 140. This approval allows CytoDyn to proceed with its planned clinical trial to evaluate leronlimab's effects on chronic inflammation. Leronlimab shows potential for treating various health conditions, including HIV and cancer, due to its ability to target multiple diseases.

In October 2022, Amgen Inc., a US-based biopharmaceutical company, acquired ChemoCentryx for approximately $3.7 billion. This acquisition is aimed at enhancing Amgen's portfolio in inflammation and nephrology by incorporating ChemoCentryx's innovative therapeutics, such as TAVNEOS (avacopan), into its product lineup. ChemoCentryx is a US-based company specializing in CCR5-related medicines.

Major companies operating in the cc chemokine receptor type 5 market are Pfizer Inc., Sorrento Therapeutics, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Avexa Limited, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical, Gilead Sciences Inc., Vertex Pharmaceuticals, Ono Pharmaceutical Co Ltd, Abcam Limited, BioLegend Inc., R&D Systems Inc, American Gene Technologies International Inc, NSJ Bioreagents, Cytodyn Inc., Affinity Biosciences.

North America was the largest region in the CC chemokine receptor type 5 market in 2023. The regions covered in the cc chemokine receptor type 5 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cc chemokine receptor type 5 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

CC chemokine receptor type 5 (CCR5) is a protein found on the surface of white blood cells that plays a crucial role in the immune system by serving as a receptor for specific chemokines. These signaling molecules guide the movement of immune cells to areas of inflammation or infection. CCR5 is notably involved in the pathogenesis of diseases such as HIV, where it acts as a co-receptor, enabling the virus to enter and infect host cells, thus making it a target for therapeutic interventions.

The main types of CCR5-related compounds include BMS-813160, AG-1105, CCL-14, DS-001, and others. BMS-813160 is a small-molecule inhibitor developed by Bristol-Myers Squibb, designed to target specific receptors or pathways and is often investigated for its potential therapeutic effects in diseases such as cancer. Distribution channels for these compounds include hospitals, clinics, online pharmacies, and retail pharmacies. They are applied in various fields, including infectious diseases, gastrointestinal conditions, immunology, and oncology, and are used by different end-users such as research institutes, pharmaceutical companies, and healthcare facilities.

The CC chemokine receptor type 5 market research report is one of a series of new reports that provides CC chemokine receptor type 5 market statistics, including CC chemokine receptor type 5 industry global market size, regional shares, competitors with an CC chemokine receptor type 5 market share, detailed CC chemokine receptor type 5 market segments, market trends, and opportunities, and any further data you may need to thrive in the CC chemokine receptor type 5 industry. This CC chemokine receptor type 5 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The CC chemokine receptor type 5 market consists of sales of receptor antagonists, monoclonal antibodies, small molecule inhibitors, and gene editing therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.